| 发明名称 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | ||
| 摘要 | The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders. | ||
| 申请公布号 | US9550780(B2) | 申请公布日期 | 2017.01.24 |
| 申请号 | US201615071797 | 申请日期 | 2016.03.16 |
| 申请人 | Auspex Pharmaceuticals, Inc. | 发明人 | Sommer Andreas;Zhang Chengzhi;Carter John;Arthur John;Bradbury Margaret;Gant Thomas;Shahbaz Manouchehr |
| 分类号 | A61P25/28;A61P25/18;A61P25/24;A61P25/00;A61P25/14;A61K31/5415;C07D455/06;C07D471/04;C07B59/00 | 主分类号 | A61P25/28 |
| 代理机构 | Baker & Hostetler LLP | 代理人 | Baker & Hostetler LLP |
| 主权项 | 1. A compound that is crystalline d6-tetrabenazine Form I having deuterium enrichment of no less than about 1%, and having an X-ray diffractogram comprising peaks, in terms of 2θ±0.2, at 6.5, 12.2, 14.4, 22.4 and 23.4; or a pharmaceutically acceptable salt or hydrate thereof. | ||
| 地址 | LaJolla CA US | ||